Sacubitril-Valsartan
Sacubitril-valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) combining sacubitril (a neprilysin inhibitor prodrug) and valsartan (an angiotensin II receptor blocker) for heart failure treatment. Sacubitril inhibits neprilysin-mediated breakdown of natriuretic peptides, bradykinin, and other vasoactive substances, while valsartan blocks AT1 receptors, producing complementary vasodilatory and cardioprotective effects. It has demonstrated superior outcomes to ACE inhibitors in patients with heart failure with reduced ejection fraction.
Molecular Weight
414.5010 g/mol
TPSA
205.00 Ų
Therapeutic Areas
Drug Classes
Mechanism of Action
Angiotensin receptor-neprilysin inhibitor (ARNI) combining neprilysin inhibition with AT1 receptor blockade.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Angiotensin receptor-neprilysin inhibitor (ARNI) combining neprilysin inhibition with AT1 receptor blockade.
SMILES
CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O.CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)O
InChI
InChI=1S/C24H29N5O3.C24H29NO5/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23;1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28);4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28)/t22-;17-,21+/m01/s1
Molecular Formula
C24H29N2O5
HBD / HBA
4 / 11
Rotatable Bonds
22
Heavy Atoms
62
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
Sacubitril-valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) combining sacubitril (a neprilysin inhibitor prodrug) and valsartan (an angiotensin II receptor blocker) for heart failure treatment. Sacubitril inhibits neprilysin-mediated breakdown of natriuretic peptides, bradykinin, and other vasoactive substances, while valsartan blocks AT1 receptors, producing complementary vasodilatory and cardioprotective effects. It has demonstrated superior outcomes to ACE inhibitors in patients with heart failure with reduced ejection fraction.
Angiotensin receptor-neprilysin inhibitor (ARNI) combining neprilysin inhibition with AT1 receptor blockade.
Key pharmacokinetic parameters for Sacubitril-Valsartan: Half-life: 11.5 hours.
Yes, Sacubitril-Valsartan is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
References & Data Sources
- PubChem — National Center for Biotechnology Information (NCBI). CID 24755620. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="sacubitril-valsartan"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/sacubitril-valsartan/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/sacubitril-valsartan/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/sacubitril-valsartan/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="sacubitril-valsartan"></drugfyi-drug>